Cy­tomX shares plum­met as Am­gen-part­nered can­cer drug yields jum­bled Phase 1 da­ta

Cy­tomX and Am­gen’s T cell en­gager showed mixed ef­fi­ca­cy sig­nals in an ear­ly tri­al in ad­vanced sol­id tu­mors, send­ing the biotech’s shares down 37% even as an­a­lysts de­fend­ed the da­ta.

The Phase 1a dose-es­ca­la­tion study test­ed CX-904 — which tar­gets the epi­der­mal growth fac­tor re­cep­tor (EGFR) and CD3 re­cep­tor — in pa­tients with ad­vanced metasta­t­ic sol­id tu­mors known to ex­press EGFR. The tri­al en­rolled 35 heav­i­ly pre­treat­ed pa­tients with a me­di­an four pri­or lines of ther­a­py at the da­ta cut­off, ac­cord­ing to a com­pa­ny re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER